Actualités

Moby summary of Intuitive Machines, Inc.'s Q2 2026 earnings call

(Updates with index/price moves, macroeconomic data and company/geopolitical news from the first par

Moby summary of American Shared Hospital Services's Q2 2026 earnings call

Mike Novogratz, the billionaire founder and CEO of the crypto-focused asset manager Galaxy Digital (Nasdaq: GLXY), has sharply reacted to the rising federal debt of the U.S. government. The U.S. federal budget deficit jumped ‌to $432 billion in July as receipts totaled $334 billion against ...

Moby summary of Aebi Schmidt Holding AG's Q2 2026 earnings call

After a steep sell-off last month, investors are chipping in again. Chip stocks were some of the biggest gainers in the S&P 500 and Nasdaq Thursday, a day when markets rose broadly.

Check out the companies making headlines yesterday:

While Wall Street pundits spent years writing the obituary for the balanced portfolio, one 90-year-old fund kept quietly compounding through rate shocks, drawdowns, and the critics. Here is why the death notice may have been premature.

Armstrong is bullish on stablecoins, DeFi applications, and tokenized stocks.

(Updates with market moves after the close.) The S&P 500 rose to a record on Thursday as traders

Artificial-intelligence adoption continued to drive demand for the company’s semiconductor solutions.

Applied Materials beat analyst estimates for its fiscal third quarter and with its guidance for fiscal Q4. But AMAT stock slid.

Intel's free cash flow has turned positive for the first time in four years, and its own capital plans decide whether it stays there.

The company made its first deployment in a contract with an important client.

A move that hurts shareholders in the short term could actually benefit investors in the end.

Most parents hope their kids will help fund retirement someday. One father decided to get a head start. After turning his son’s lottery winnings into a six-figure investment account, he argued that the original money still belonged to his son...

The AI boom often centers on productivity – doing more and doing it faster. But AI also allows for automated attacks at record speeds.

Analysts surveyed by The Wall Street Journal were expecting a 0.2% gain. The reading follows a slight slowdown in CPI reported Wednesday and added to expectations that the Federal Reserve can hold off on raising rates for now. The market-implied likelihood of a hike at its September meeting is now around 35%, down from 55% a week ago according to CME FedWatch.

The U.S. stock market rose to a record following the latest sign that inflation is getting less bad. The Dow Jones Industrial Average added 0.1%, and the Nasdaq composite gained 0.8%. The Nasdaq composite rose 214.54 points, or 0.8%, to 26,803.03.

Lam Research said on Thursday it intends to invest more than $3 billion in ‌the next five years to expand its ‌global research and development lab network, as it seeks to increase ​experiment capacity and speed up product development. The U.S. chip equipment maker said the multi-site expansion is expected to increase its experiment capacity by over 50%. • Lam Research is making the investment with the intention of staying ahead of customers' ​needs as ​the pace of innovation ​requires chips with new ‌architectures, different materials and complex features engineered with nanoscale precision, CEO Tim Archer said.

In one of his last public appearances as CEO, Tim Cook offered Secretary of Commerce Howard Lutnick a tour of a facility meant to highlight its investments in U.S. supply chains.

The appointment signals a move toward performance and metrics frameworks. OpenAI must improve reliance on the tracking tools it offers advertisers before more will increase their ad budgets with OpenAI.

Semiconductor machinery manufacturer Applied Materials (NASDAQ:AMAT) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 24.8% year on year to $9.12 billion. On top of that, next quarter’s revenue guidance ($10.25 billion at the midpoint) was surprisingly good and 6.1% above what analysts were expecting. Its non-GAAP profit of $4.02 per share was 18.4% above analysts’ consensus estimates.

Wrapping up Q2 earnings, we look at the numbers and key takeaways for the health insurance providers stocks, including Oscar Health (NYSE:OSCR) and its peers.

One of the biggest S&P 500 funds on the planet holds hundreds of billions in retirement savings, yet most of the people who own it have never seen its ticker and cannot buy a single share on their own.

Meta is teaming up with NABTU to tap a massive skilled labor pipeline as the tech giant ramps up construction and maintenance of AI infrastructure in the U.S.

Costco Wholesale (NasdaqGS:COST) is rolling out Out Of The Woods LLC's XL Tote Trio reusable bag set in select West Coast warehouses, with online availability expected soon. The XL Tote Trio features environmentally focused materials and design, reflecting Costco's wider push into sustainable consumer lifestyle products. This launch adds a new category of eco-friendly, reusable totes to Costco's in-warehouse assortment, separate from recent supplement and snack product launches. Investors...

Freeport-McMoRan stock has delivered a strong 118.9% total return over the past five years, yet the current valuation checks and market multiples suggest the shares are not an obvious bargain at today's levels. Over the last 5 years Freeport-McMoRan has returned 118.9%, which puts extra focus on whether the recent share price reflects a full valuation for the business. Expectations around copper focused growth can support the current price, while any disappointment in project delivery or...

Options are priced for a calmer stretch than the stock just delivered, and even that assumption leaves room to lose close to half a position or nearly double it.

Price target commentary for Merck has shifted toward a US$140 to US$155 range, anchored by a modest uplift in fair value from US$132.78 to US$136.85. Analysts link these higher targets to research that highlights Merck’s pipeline progress, recent business development moves and continued focus on late stage therapeutics. As you read on, you will see how to track these moving pieces and what they could mean for the evolving Merck story in the coming years. Stay updated as the Fair Value for...